Teva Pharmaceutical Industries Valuation

Q: What is the Fair Price of TEV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

TEV (€18.1) is trading below our estimate of [[fair value]] (€70.41)

Is TEV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TEV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TEV (€18.1) is trading below our estimate of fair value (€70.41)

Significantly Below Fair Value: TEV is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TEV?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for TEV. This is calculated by dividing TEV's market cap by their current preferred multiple.
What is TEV's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	n/a

TEV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.1x
Enterprise Value/EBITDA	7.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does TEV's PS Ratio compare to its peers?

The above table shows the PS ratio for TEV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	10x
THQM Tchaikapharma High Quality Medicines AD	32.5x	n/a	лв1.6b
SFA Sopharma AD	0.5x	n/a	лв974.5m
SDZ Sandoz Group	1.9x	5.7%	CHF 17.1b
GALD Galderma Group	5.2x	11.6%	CHF 19.4b
TEV Teva Pharmaceutical Industries	1.2x	2.6%	€19.7b

Price-To-Sales vs Peers: TEV is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (10x).

Price to Earnings Ratio vs Industry

How does TEV's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	15.3%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	15.3%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: TEV is good value based on its Price-To-Sales Ratio (1.2x) compared to the European Pharmaceuticals industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is TEV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TEV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate TEV's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TEV forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	€18.10	€20.83 +15.1%	10.8%	€24.22	€16.77	n/a	9
Nov ’25	€16.80	€20.16 +20.0%	13.3%	€24.04	€15.72	n/a	9
Oct ’25	n/a	€19.19 0%	14.2%	€23.47	€14.44	n/a	9
Sep ’25	n/a	€18.36 0%	16.2%	€21.46	€13.29	n/a	9
Aug ’25	n/a	€18.62 0%	15.8%	€22.24	€13.77	n/a	9
Jul ’25	n/a	€17.51 0%	16.6%	€21.49	€13.55	n/a	10
Jun ’25	n/a	€16.47 0%	15.1%	€20.31	€13.39	n/a	10
May ’25	n/a	€14.67 0%	15.0%	€17.71	€10.25	n/a	10
Apr ’25	n/a	€13.87 0%	15.5%	€17.39	€10.07	n/a	10
Mar ’25	n/a	€13.63 0%	17.5%	€17.56	€10.17	n/a	10
Feb ’25	n/a	€12.19 0%	14.6%	€14.72	€9.20	n/a	10
Jan ’25	n/a	€10.28 0%	16.5%	€12.82	€7.33	n/a	11
Dec ’24	n/a	€10.08 0%	16.7%	€12.78	€7.30	n/a	10
Nov ’24	n/a	€10.41 0%	15.6%	€13.32	€7.61	€16.80	10
Oct ’24	n/a	€10.31 0%	15.6%	€13.24	€7.57	n/a	10
Sep ’24	n/a	€9.27 0%	17.4%	€12.72	€7.27	n/a	10
Aug ’24	n/a	€8.73 0%	17.4%	€12.47	€7.13	n/a	10
Jul ’24	n/a	€9.00 0%	19.6%	€12.88	€6.44	n/a	9
Jun ’24	n/a	€9.07 0%	19.3%	€13.06	€6.53	n/a	9
May ’24	n/a	€9.27 0%	22.5%	€12.74	€6.37	n/a	8
Apr ’24	n/a	€9.31 0%	21.1%	€12.89	€6.44	n/a	9
Mar ’24	n/a	€9.50 0%	20.2%	€13.11	€6.55	n/a	10
Feb ’24	€9.32	€9.23 -1.0%	20.5%	€12.00	€6.46	n/a	10
Jan ’24	n/a	€9.06 0%	17.6%	€12.26	€6.60	n/a	10
Dec ’23	€8.40	€9.33 +11.0%	17.3%	€12.50	€6.73	n/a	10
Nov ’23	n/a	€10.44 0%	12.3%	€13.18	€8.11	n/a	10

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.